Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Mulberry plans £20m fundraising, expects FY losses to widen

(Sharecast News) - Luxury handbag maker Mulberry tumbled on Friday as it announced plans to raise £20m of additional capital to help fund its growth strategy and meet its medium-term revenue, profitability and cash generation targets, and said it expects a widening of its full-year losses. Following a post FY25 year-end review by the executive management, "and in light of an even more challenging trading environment seen at a macro level", the board concluded that it will require additional capital to fund its growth strategy and achieve its desired financial targets.

The firm's medium-term goals are annual revenues of £200m and an earnings before interest and tax margin of 15%.

The company said majority shareholder Challice has confirmed it would be willing to underwrite the fundraising in full if required. However, Mulberry believes its prospects are stronger if its other major shareholder Frasers Group also participates.

Mulberry said its board has been engaging with Challice and Mike Ashley's Frasers to reach agreement on the final structure and terms of the fundraising.

"Whilst these discussions are ongoing, the board notes that it may not be possible for all parties to agree fully on the structure of the fundraising, in which case the board, or an independent committee thereof, will conclude on the most appropriate structure for the company," it said.

News of the planned fundraising came as the company said it expects FY25 revenues to be around £120m, down from £152.9m in 2024 and an underlying pre-tax loss of about £23m, compared to £22.6m a year earlier.

Mulberry said trading in the 11 weeks since the FY25 year-end has been in line with the board's expectations and that it does not expect "material" overall revenue growth in the current financial year.

Chief executive Andrea Baldo said: "When I outlined our strategy in January, I set out a clear two-phased approach. In the near term, we are firmly in turnaround mode - focused on rebuilding profitability and gross margin, while strategically investing in brand building initiatives.

"Since then, we've taken decisive steps to improve performance and lay the groundwork for sustainable growth. These include securing UK distribution deals with Flannels and John Lewis, expanding international reach through new doors in Nordstrom (US) and David Jones (AU), and enhancing our product offer by growing our icon families in full price stores and optimising our inventory levels for outlet stores.

"We've refreshed the executive team, aligned talent to our revised strategy, and launched a new brand campaign to drive customer engagement. Operationally, we've enhanced customer service through a new incentive model linked to in-store conversion, improved relationships with our supply chain partners and built a robust wholesale pipeline for FY26. Alongside this, we've taken action to reduce costs - restructuring head office and exiting unprofitable stores - delivering a lower run-rate cost base into FY26.

"Following our year-end review, the board and I are confident that, with additional funding, we can accelerate momentum and deliver against our targets at pace."

At 1550 BST, the shares were down 15% at 95.50p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.